FERMENTALG WKN: A1103M ISIN: FR0011271600 Kürzel: 1F6 Forum: Aktien Thema: Hauptdiskussion

Leider totes Geld. Es passiert hier wenig bis garnichts.

The technological development of these two breakthrough products has been completed and the first industrial batches have been produced and delivered to Fermentalg's commercial partners ahead of their upcoming market launches. Confirmation of the 2026 commercial target At the end of this first quarter and taking into account the launch schedules for the new BioSolutions, Fermentalg confirms that it anticipates a sharp acceleration in its growth in the second half of 2026, with the reaffirmed ambition of reaching €20 million in annual revenue. Next publication: revenue for the first half of 2026, 16 July 2026 (after market close) About Fermentalg Fermentalg is a leading player in the development and production of sustainable BioSolutions derived from microorganisms. The company designs, produces and markets innovative ingredients for the human and animal nutrition markets, in line with the ‘One Health' principle. Committed to the United Nations Sustainable Development Goals, Fermentalg helps to improve human well-being, animal health and environmental conservation through natural, high-performance and responsible solutions. Fermentalg shares are listed on Euronext Growth Paris (FR0011271600 - ALGAE) and is eligible for the PEA-PME scheme. It has been awarded an ‘Exemplary' rating (90/100) by EthiFinance ESG Ratings, a rating agency specialising in the ESG performance of SMEs listed on European markets, in support of Socially Responsible Investment (SRI). For further information: www.fermentalg.com

commercial launches of the new BioSolutions Download this press release in PDF format Record turnover of €3.7 million in the first quarter of 2026; 42% growth in sales excluding aquaculture; Significant rise in fish oil prices, opening up potential for growth in the second half of 2026; Commercial launches of the ΩRIGINS™ EPA/DHA range and the natural blue colourant Galdieria Blue, with an expected commercial impact in the second half of 2026; Confirmation of the ambition to achieve €20 million in turnover in 2026. Libourne, 5 May 2026 – Fermentalg, a leading player in the development, production and sale of sustainable BioSolutions derived from microorganisms, presents its unaudited turnover for the first quarter of 2026 and provides an update on its latest commercial progress. Record commercial activity driven by high-margin segments Fermentalg achieved revenue of €3.7 million in the first quarter of 2026, a new high for the start of the year, with the previous record having been set in early 2025 (€3.6 million). This commercial performance is all the more remarkable given that, as announced at the time of the publication of its 2025 annual results, the Company has temporarily shifted away from the aquaculture segment—which features high volumes but low margins—and which had accounted for more than one-quarter of revenue in the first quarter of 2025 (€1.0 million). Consequently, sales of the lipid range (ΩRIGINS™[1]) for the other, higher value-added segments (dietary supplements and infant nutrition) rose by 42% between the first quarter of 2025 and the first quarter of 2026 (€3.7 million compared with €2.6 million). Trends favouring the substitution of fish oils Beyond the commercial performance at the start of the financial year, Fermentalg is seeing a growing number of signs pointing towards the increasing substitution of fish oil with BioSolutions. Following a very difficult end to the 2024 financial year, during which fish oil prices fell by two-thirds, and a relative stabilisation in 2025, the first few months of 2026 have seen a significant rise in fish oil prices[2] . This trend is linked in particular to a drastic reduction in fishing quotas, lower yields and continued strong demand for products with a high concentration of omega-3. BioSolutions' economic competitiveness is thus gradually being restored, facilitating the transition for food manufacturers, which could enable the Company to return to the aquaculture segment by the end of the year. Promising prospects thanks to the launches of the ΩRIGINS™ EPA/DHA range and Galdieria Blue It is against this structurally favourable backdrop that Fermentalg is preparing to launch its two major new innovations: A new range of ΩRIGINS™ algal oil, rich in EPA/DHA, a genuine alternative to fish oils for easy substitution as a functional ingredient, thanks to its equivalent composition and nutritional profile; The natural blue colourant Galdieria Blue™, already approved by the US Food and Drug Administration (FDA), and which received a favourable opinion from the European Food Safety Authority (EFSA) in March 2026, paving the way for marketing authorisation in Europe.

Termine fürs Jahr.

Libourne - January 15, 2025 - Fermentalg (Euronext Growth / ALGAE) publishes its financial agenda for the year 2024. DateNatureJanuary 14, 20252024 Four quarter financial information (after market closing)March 20, 20252024 Annual results (after market closing)April 2, 20252025 First quarter financial information (after market closing)July 8, 20252025 Second quarter financial information (after market closing)Septembre 11, 20252025 Half-year results (after market closing)Octobre 7, 20252025 Third quarter financial information (after market closing) This agenda is given for information only and may be modified if necessary.

Record annual sales in 2024 and trajectory confirmed for 2026 Download this press release in PDF format Libourne - January 14, 2025 - Fermentalg (Euronext Growth / ALGAE) announces record annual sales for 2024[1] and confirms its growth trajectory to reach profitability by 2026. Sales multiplied by almost 3 in 1 year Fermentalg closed a record 2024 financial year in terms of sales, with sales of €11.5 million, significantly higher than those of 2023 (€4 million) and the target set at the beginning of last year (€10 million). This performance is all the more remarkable given that Fermentalg had to deal with order cancellations and deferrals from two major customers at the end of the year, which should have enabled it to significantly exceed the target revised upwards during the year (€12 million). Expanding into new market segments One of the major challenges of the new commercial roadmap, launched at the end of 2023[2], was Fermentalg's entry into new market segments for nutritional lipids. This long-term strategy (sales cycles of around 18 months) is already bearing fruit, with the first significant orders in infant nutrition (12% of 2024 sales) and the first referencing in animal nutrition (7%). Initial contacts have also been made in aquaculture. A confirmed growth ambition in the short and medium term This conquest of new segments will be a major driver of growth in 2025 and beyond. In early February, Fermentalg will detail its action plan for 2025, which will combine the continued acceleration of sales in nutritional lipids, the start-up of commercial activity in natural food colorants, and the continued development of new growth drivers stemming from R&D programs. The coming year should consolidate the trajectory towards achieving the sales target of at least €25m by 2026. Next publication: annual results 2024, March 20, 2025 (after market close) About Fermentalg An expert in the research and bioindustrial exploitation of microalgae, Fermentalg aims to offer sustainable solutions and innovative products that contribute to the development of healthy, natural and high-performance products. Our business: the development, production and marketing of sustainable solutions and active ingredients derived from microalgae, for nutrition, health and the environment. Nutritional lipids, alternative proteins, natural food colorings and innovative environmental solutions make up our company's current and future offering. Fermentalg shares are listed on Euronext Growth Paris (FR0011271600 - ALGAE) and are PEA-PME eligible. It has received an Exemplary rating (90/100) from EthiFinance ESG Ratings, a rating agency specializing in the ESG performance of SMEs listed on European markets, in favor of Socially Responsible Investment Newsletter heute.

🎉

Ich hoffe 3€

The documents relating to the General Meeting provided to shareholders must be published on the Company's website, no longer twenty-one (21) days before the date of the General Meeting but only on the date of convocation. The notice of availability of the preparatory documents for the general meeting will no longer be required. The publication on the Company's website of the results of the votes and the minutes of the general meeting will no longer be required. The Company will no longer be subject to the «say on pay» mechanism providing for the prior vote of shareholders on the executive remuneration policy, the subsequent vote on the remuneration report and the approval of individual executive remuneration.  The Corporation will no longer be held accountable for internal control or risk management. The Company will no longer be subject to the provisions of Articles L. 823-19 and following of the French Commercial Code as regards audit committees, but may maintain this committee if it so wishes. Indicative timetable for the transfer to Euronext Growth Paris In the coming days, an application to delist the shares of Euronext Paris' Fermentalg and their concomitant admission to Euronext Growth Paris will be filed with Euronext Paris. Subject to the agreement of Euronext Paris, admission to Euronext Growth Paris will take place within a minimum period of two (2) months from the General Meeting that approved the Transfer, at the earliest on 2 April 2024, and within the limit of twelve (12) month following the date of the General Meeting.  The Company will be supported in its transfer project on Euronext Growth Paris by CIC Market Solutions as a listing sponsor. Next publication: results of the 2023 financial year and turnover of the 1st quarter 2024, 3 April 2024 (after the closing of the markets)

In terms of periodic information: The half-yearly report, including the half-yearly (and consolidated) financial statements and an activity report relating to these half-yearly financial statements, will be published within four months of the end of the first half of the Company's financial year, instead of the three-month period applicable to companies whose securities are admitted to trading on a regulated market. The statutory auditors' review of the half-year accounts will be maintained, although no longer required. Some information required under the management and corporate governance report will be reduced. The Company will continue to prepare consolidated financial statements in accordance with IFRS accounting standards. The Company will continue with the current publication of its quarterly financial information. For ongoing information: Euronext Growth Paris being a multilateral trading system, the Company would remain subject to the provisions applicable to permanent market information, and in particular to the provisions of the Regulation (EU) n°596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (" MAR"). Any company listed on Euronext Growth Paris must ensure the effective and complete dissemination of the so-called regulated information. In addition, the officers of the Company and persons closely associated with them would remain subject to the obligation to report transactions in the Company's shares or debt instruments in accordance with section 19 of the MAR Regulation. As regards the protection of minority shareholders: Unless otherwise agreed, the protection of minority shareholders is ensured on Euronext Growth Paris by the mandatory public offer mechanism in the event of crossing, directly or indirectly, alone or in concert, the 50% threshold of the capital or voting rights. Only crossings, up or down, of thresholds of 50% and 95% of the capital or voting rights are to be reported to the AMF and the Company, subject to crossings of statutory thresholds to be reported to the Company.

Subject to the agreement of Euronext Paris, the listing of the company on Euronext Growth Paris will be carried out as part of an accelerated procedure for the admission to trading of the company's existing shares, without issuing new shares. Reasons for the transfer This project aims to enable the company Fermentalg S.A. to reduce the constraints associated with the regulated market Euronext Paris and the resources committed to meet them. Euronext Growth Paris offers a simplified operation, more adapted to the size, activity, market capitalization and needs of the Company, while allowing it to continue to benefit from the attractiveness of the financial markets. Consequences of the transfer In accordance with current regulations, the Company wishes to inform its shareholders of certain possible consequences of such a Transfer (non-exhaustive list):